Mont-Saint-Guibert, Belgium –Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of Dr. Vincent Brichard as Vice President immuno-oncology. In this role, Dr. Brichard will lead the newly acquired immuno-oncology technology platform of Cardio3 BioSciences.
Vincent Brichard is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. In 2002, he joined GlaxoSmithKline Biologicals, where he led the Cancer Vaccines Business Unit. Until recently, Vincent was the Senior Vice President of the Immunotherapeutics Business Unit, and member of the Vaccines Executive team at GSK Biologicals
Vincent Brichard will give all support required to build another asset of the Company, by driving, from preclinical towards commercialisation, the development of the products of the immunooncology platform.
Vincent Brichard will continue to hold other non-executive positions with other companies, and will continue to bring his expertise to those and other companies in the future.
Dr. Vincent Brichard, Vice President Immuno-oncology at Cardio3 BioSciences, said: “I am pleased to have the opportunity to contribute to the development of Cardio3 BioSciences in the very exciting field of Immuno-Oncology. With the newly acquired CAR T-cells targets, I am confident that Cardio3 BioSciences will have the opportunity to become a major player in this promising field in the near future.”
Dr. Christian Homsy, CEO of Cardio3 BioSciences, commented: “We are extremely pleased to be able to count on Vincent Brichard’s expertise to develop our new immuno-oncology franchise. His tremendous experience and closed ties with the pharmaceutical industry will be instrumental to lead our new CAR T-cells technology platform to clinical success in the coming months, and generate significant value creation opportunities to our Company.”
